- Sidney Mazel Joins MedImmune as Senior Vice President of Product Planning and Portfolio Management -
GAITHERSBURG, Md., June 12, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- MedImmune, Inc.
(Nasdaq: MEDI) today announced that Sidney Mazel, Ph.D. has joined the
management team as senior vice president, product planning and portfolio
management. In this newly created position, Dr. Mazel will lead the life-cycle
management of the company's expanding portfolio of products and product
candidates. Specifically, he will be responsible for new product planning,
project management, market research and competitive intelligence.
"Sid will be bridging between product development and commercialization to
drive long-term strategic planning to maximize the value of our existing
products and our products in development," said David M. Mott, president and
chief executive officer. "He brings tremendous capabilities in life-cycle
management and strategic planning from both his experience in industry at
Merck and Wyeth and from his background in consulting at Pittiglio, Rabin,
Todd and McGrath."
Prior to joining MedImmune, Dr. Mazel held a number of senior leadership
positions at Merck & Co., most recently holding the title of vice president of
worldwide marketing planning for Merck's obesity and atherosclerosis
franchise. In this position, he had global responsibility for the division's
long-term business strategy, new product development, market and competitive
intelligence, life-cycle strategies, licensing, labeling and opinion leader
management. At Merck, he was also selected to lead a corporate-wide franchise
life-cycle management project to ensure optimal strategic planning across all
therapeutic areas. Previously, Dr. Mazel was a principal with Pittiglio,
Rabin, Todd and McGrath, a consulting firm that provides services to improve
strategic planning, technology management, product development and marketing
operations for leading pharmaceutical and biotechnology companies. Prior to
his consulting work, Dr. Mazel held a number of increasingly responsible
positions in the research and marketing departments at Wyeth Pharmaceuticals.
He received his bachelor's and master's degrees from George Washington
University, and his Ph.D. from the University of Maryland.
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious disease,
cancer and inflammatory diseases. With more than 2,300 employees worldwide,
MedImmune is headquartered in Maryland. For more information, visit the
company's website at http://www.medimmune.com.
SOURCE MedImmune, Inc.
Media: Jamie Lacey, +1-301-398-4035, Investors: Peter Vozzo, +1-301-398-4358